Shanghai, China — Recently, MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) has received marketing approval for its second-generation balloon catheter , Alwide^® Plus Balloon Catheter (hereinafter referred to as "Alwide^® Plus") from Russian State Food and Drug Administration(RZN).

On September 4, 2023, at 15:00 local time, the VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow Liberty^®"), self-developed by MicroPort^® CardioFlow, VitaFlow Liberty^® was presented at the Police General Hospital in Thailand. Under the leadership of Prof. Luo Jianfang from Guangdong Provincial People's Hospital, Prof. Anuruck Jeamanukoolkit, an expert from the hospital, together with his team, successfully performed the first implantation of VitaFlow Liberty^® in Thailand. Postoperative imaging showed that the patient's valve was in good shape and position, with no perivalvular leakage or coronary occlusion, and the surgery was a complete success.

Shanghai, China - As a new generation of TAVI product developed by MicroPort^® CardioFlow Medtech Corpration, VitaFlow Liberty^® is the first and only motorized retrievable transcatheter aortic valve system in the world. Recently, MicroPort^® CardioFlow team accompanied the expert team from four renowned hospitals in Thailand to Xiamen Cardiovascular Hospital Xiamen University to observe the successful implantation of a patient with moderate aortic stenosis combined with severe regurgitation by the local physician team using the product, which has been reprinted and reported by a number of media outlets.